NAROPIN (ropivacaine hydrochloride)
Naropin is a local anesthetic used to provide regional or local anesthesia for adult patients undergoing surgical procedures. It helps patients manage acute pain, such as during labor or following surgery, through methods like epidural infusions or nerve blocks. This medication is often used for major surgeries, including cesarean sections, to ensure effective pain control and anesthesia.
How NAROPIN Works
Naropin works by blocking the generation and conduction of nerve impulses within the body. It increases the threshold for electrical excitation and slows the propagation of these impulses, effectively preventing the sensation of pain. This process results in a progressive loss of nerve function, beginning with pain and temperature and moving toward touch and muscle tone.
Development Insights
Details
- Status
- Prescription
- First Approved
- 1996-09-24
- Patent Cliff
- 2026
- Routes
- INJECTION
- Dosage Forms
- SOLUTION
NAROPIN Approval History
What NAROPIN Treats
1 indicationsNAROPIN is approved for 1 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Pain
NAROPIN Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to NAROPIN
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
7 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07519109 | SYH9089-001 | Ph 1 | not yet recruiting | Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. |
| NCT07353307 | TRD303-Ⅲ -02 | Ph 3 | recruiting | A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. |
| NCT03360214 results posted | AAAQ4708 | Ph 4 | completed | PEMF and PEC Blocks in Mastectomy Reconstruction Patients |
| NCT03513445 | ORSU-2018-26340 | Ph 3 | withdrawn | Peri-Incisional Drug Injection in Lumbar Spine Surgery |
| NCT04368364 results posted | HSC-MS-20-0143 | Ph 4 | terminated | A Randomized Control Trial Comparing Analgesic Benefits of Ultrasound-guided Single vs Continuous Quadratus Lumborum Blocks (QLB)vs Intrathecal Morphine(ITM) for Post Cesarean Section Pain |
| NCT03591146 results posted | TLC590A1001 | Ph 1, Ph 2 | completed | Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management |
| NCT02438852 | 4B-14-4 NCI-2015-00279, 4B-14-4 | Ph 3 | withdrawn | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NAROPIN FDA Label Details
Indications & Usage
FDA Label (PDF)NAROPIN is indicated for the treatment of Pain.
NAROPIN Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for NAROPIN
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2026
- • 26 active patents
Trial Analysis
- • 8 total trials
- • Stage: Stable
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment